Provided is the use of a composition comprising nanoparticles comprising paclitaxel and an albumin in the manufacture of a medicament for treating non-small cell lung cancer (NSCLC), wherein the medicament is to be administered with a platinum-based agent, wherein treatment is based on the patient being at least 70 years old and the NSCLC being squamous cellular carcinoma. Further provided are methods of assessing whether a patient will respond to a treatment comprising nanoparticles comprising paclitaxel and an albumin and a platinum-based agent on basis that the cancer is squamous cell carcinoma and the patient is at least 70 years old.
